What it is
"Wolverine" is a nickname used in marketing for a combination of BPC-157 and TB-500 in one product. It is not a medical or regulatory term.
Each ingredient is described on its own page: BPC-157 is based on part of a protein found in gastric juice, and TB-500 is based on a short section of thymosin beta-4.
How it is being studied
We found no published clinical trials of this combination in people as of November 2026. Research on each ingredient on its own comes mostly from laboratory and animal studies, and human data are very limited.
Combining two substances adds questions that studies of either one alone cannot answer, such as how they interact and how side effects should be attributed.
FDA status
Neither BPC-157 nor TB-500 is FDA-approved, and no combination product has been approved.
FDA has published safety concerns about each ingredient in its review of substances nominated for compounding, including concerns about peptide-related impurities and limited safety information. Neither is on FDA's list of bulk substances that pharmacies may use to compound medications. An FDA advisory committee discussed both in July 2026; as of November 2026, FDA had not published a final decision on either.
Anti-doping rules
Both ingredients are prohibited at all times under World Anti-Doping Agency rules: BPC-157 in class S0 and TB-500 in class S2.
If you are subject to drug testing in your sport, check with your anti-doping organization before using any product.
Sources
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks
- FDA: Bulk drug substances used in compounding under section 503A
- FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026
- USADA: BPC-157 peptide prohibited
- USADA: What's new on the 2027 WADA Prohibited List
- World Anti-Doping Agency: Prohibited List
Talk to our medical team about whether any treatment is right for you.
Contact usThis page is general educational information. It is not medical advice and does not describe or offer any treatment. Regulatory status can change; this page reflects the sources listed as of the review date.